Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.36 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.36 |
| ▸ | CACNB4 | O00305 | 3/20 | 0.35 |
| ▸ | CACNA1A | O00555 | 3/20 | 0.35 |
| ▸ | CACNA1G | O43497 | 3/20 | 0.35 |
| ▸ | CACNG3 | O60359 | 3/20 | 0.35 |
| ▸ | CACNA1F | O60840 | 3/20 | 0.35 |
| ▸ | CACNA1H | O95180 | 3/20 | 0.35 |
| ▸ | CACNB3 | P54284 | 3/20 | 0.35 |
| ▸ | CACNA2D1 | P54289 | 3/20 | 0.35 |
| ▸ | CACNG7 | P62955 | 3/20 | 0.35 |
| ▸ | CACNA1B | Q00975 | 3/20 | 0.35 |
| ▸ | CACNA1D | Q01668 | 3/20 | 0.35 |
| ▸ | CACNB1 | Q02641 | 3/20 | 0.35 |
| ▸ | CACNG1 | Q06432 | 3/20 | 0.35 |
| ▸ | CACNB2 | Q08289 | 3/20 | 0.35 |
| ▸ | CACNA1S | Q13698 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4304429 | 0.89 | KCNH2 (0.38) | CYP2C19CYP2C9AKR1A1AKR1B1GRIN2B | |
| Formaldehyde SCHEMBL14801698 | 0.87 | SNCA (0.39) | CYP2C19CYP2C9CYP3A4AKR1A1AKR1B1 | |
| SCHEMBL1120470 | 0.86 | HTR6 (0.46) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL1120440 | 0.83 | ADRB2 (0.38) | CYP2C9AKR1A1AKR1B1ADRA2AADRA1A | |
| SCHEMBL1120530 | 0.81 | BCHE (0.42) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL1120581 | 0.77 | SNCA (0.37) | AKR1A1AKR1B1TBXAS1 | |
| SCHEMBL1120723 | 0.74 | SNCA (0.38) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL14801699 | 0.72 | CNR1 (0.35) | CYP2C19CYP2C9CYP3A4AKR1A1AKR1B1 | |
| SCHEMBL1120448 | 0.71 | CNR1 (0.43) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F | |
| SCHEMBL1120695 | 0.69 | KCNH2 (0.48) | CACNB4CACNA1ACACNA1GCACNG3CACNA1F |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9469641-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-9260429-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| CN-102083830-B | Pyrido [3,4-b ] indoles and methods of use | MEDIVATION TECHNOLOGIES INC | 2014-11-12 | — | — | CN | disclosed |
| US-20130190323-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130184306-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130131077-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130079352-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-8338447-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2280968-A2 | PYRIDO [3, 4-B]INDOLES AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2011-02-09 | — | — | EP | disclosed |
| US-20090270412-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2009-10-29 | — | — | US | disclosed |
| WO-2009120717-A2 | PYRIDO [3, 4-B] INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184306-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | CYP2C19 363/4885CYP2C9 1195/4885CYP3A4 541/4885 |
| US-20130079352-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | CYP2C19 363/4885CYP2C9 1195/4885CYP3A4 541/4885 |
| US-20090270412-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | CYP2C19 363/4885CYP2C9 1195/4885CYP3A4 541/4885 |
| US-20130190323-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | CYP2C19 363/4885CYP2C9 1195/4885CYP3A4 541/4885 |
| US-20130131077-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR2C, HTR4 | CYP2C19 322/4885CYP2C9 1021/4885CYP3A4 500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.